Vistagen Therapeutics, Inc.

NasdaqCM:VTGN Stok Raporu

Piyasa değeri: US$84.1m

Vistagen Therapeutics Temettü

Temettü kriter kontrolleri 0/6

Vistagen Therapeutics does not have a record of paying a dividend.

Anahtar bilgiler

n/a

Temettü verimi

-153.9%

Geri Alım Getirisi

Toplam Hissedar Getirisi-153.9%
Gelecekteki Temettü Verimin/a
Temettü Büyümesin/a
Bir sonraki temettü ödeme tarihin/a
Eski temettü tarihin/a
Hisse başına temettün/a
Ödeme oranın/a

Son temettü güncellemeleri

Güncelleme yok

Recent updates

VistaGen to proceed with phase 3 anxiety nasal spray trial following interim analysis

Sep 08

VistaGen drops 80% as late-stage study for anxiety therapy fails

Jul 22

Here's Why We're Not Too Worried About VistaGen Therapeutics' (NASDAQ:VTGN) Cash Burn Situation

Apr 10
Here's Why We're Not Too Worried About VistaGen Therapeutics' (NASDAQ:VTGN) Cash Burn Situation

VistaGen Therapeutics added to Russell 2000 Index

Jun 16

VistaGen Therapeutics (NASDAQ:VTGN) Is In A Strong Position To Grow Its Business

Jun 07
VistaGen Therapeutics (NASDAQ:VTGN) Is In A Strong Position To Grow Its Business

VistaGen initiates late-stage trial of PH94B in social anxiety disorder

May 26

VistaGen names new chief commercial officer

May 04

How Does VistaGen Therapeutics' (NASDAQ:VTGN) CEO Salary Compare to Peers?

Feb 16
How Does VistaGen Therapeutics' (NASDAQ:VTGN) CEO Salary Compare to Peers?

VistaGen Therapeutics regains Nasdaq listing compliance

Jan 06

VistaGen Therapeutics slumps in after hours trade on underwritten public offering

Dec 17

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: Insufficient data to determine if VTGN's dividends per share have been stable in the past.

Büyüyen Temettü: Insufficient data to determine if VTGN's dividend payments have been increasing.


Piyasaya Karşı Temettü Getirisi

Vistagen Therapeutics Piyasaya Karşı Temettü Getirisi
VTGN temettü verimi piyasa ile karşılaştırıldığında nasıldır?
SegmentTemettü Verimi
Şirket (VTGN)n/a
Pazarın Alt %25'i (US)1.5%
Pazarın En İyi %25'i (US)4.5%
Sektör Ortalaması (Biotechs)2.2%
Analist tahmini (VTGN) (3 yıla kadar)n/a

Önemli Temettü: Unable to evaluate VTGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Yüksek Temettü: Unable to evaluate VTGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: Insufficient data to calculate VTGN's payout ratio to determine if its dividend payments are covered by earnings.


Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: Unable to calculate sustainability of dividends as VTGN has not reported any payouts.


Güçlü temettü ödeyen şirketleri keşfedin